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Abstract
Objective To investigate whether an internet based, nurse led vascular
risk factor management programme promoting self management on top
of usual care is more effective than usual care alone in reducing vascular
risk factors in patients with clinically manifest vascular disease.
Design Prospective randomised controlled trial.
Setting Multicentre trial in secondary and tertiary healthcare setting.
Participants 330 patients with a recent clinical manifestation of
atherosclerosis in the coronary, cerebral, or peripheral arteries and with
at least two treatable risk factors not at goal.
Intervention Personalised website with an overview and actual status
of patients’ risk factors and mail communication via the website with a
nurse practitioner for 12 months; the intervention combined self
management support, monitoring of disease control, and drug treatment.
Main outcome measures The primary endpoint was the relative change
in Framingham heart risk score after 1 year. Secondary endpoints were
absolute changes in the levels of risk factors and the differences between
groups in the change in proportion of patients reaching treatment goals
for each risk factor.
Results Participants’ mean age was 59.9 (SD 8.4) years, and most
patients (n=246; 75%) were male. After 1 year, the relative change in
Framingham heart risk score of the intervention group compared with
the usual care group was −14% (95% confidence interval −25% to −2%).
At baseline, the Framingham heart risk score was higher in the
intervention group than in the usual care group (16.1 (SD 10.6) v 14.0
(10.5)), so the outcome was adjusted for the separate variables of the
Framingham heart risk score and for the baseline Framingham heart
risk score. This produced a relative change of −12% (−22% to −3%) in
Framingham heart risk score for the intervention group compared with
the usual care group adjusted for the separate variables of the score
and −8% (−18% to 2%) adjusted for the baseline score. Of the individual
risk factors, a difference between groups was observed in low density
lipoprotein cholesterol (−0.3, −0.5 to −0.1, mmol/L) and smoking (−7.7%,
−14.9% to −0.4%). Some other risk factors tended to improve (body
mass index, triglycerides, systolic blood pressure, renal function) or
tended to worsen (glucose concentration, albuminuria).
Conclusion An internet based, nurse led treatment programme on top
of usual care for vascular risk factors had a small effect on lowering
vascular risk and on lowering of some vascular risk factors in patients
with vascular disease.
Trial registration Clinical trials NCT00785031.
Introduction
Patientswitharecentclinicalmanifestationofavasculardisease
(such as myocardial infarction, stroke, or peripheral arterial
disease) are at increased risk for developing a new vascular
event or death.
1 More patients survive an acute vascular event
nowadays, and as a consequence the total number of patients
in the chronic phase of vascular disease is increasing.
Established strategies to reduce vascular risk are treating
hypertension,reducinglowdensitylipoproteincholesterol,using
platelet inhibitors, controlling weight, stopping smoking, and
increasing physical exercise.
2-5 Treatment of these risk factors,
alone or in combination, has been shown to be very effective
in reducing the risk of recurrent vascular events (myocardial
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Research
RESEARCHinfarction, ischaemic stroke) and death.
6 However, in daily
clinical practice, treatment goals are often not reached. In a
prospective cohort study in patients with established vascular
diseaseortype2diabetes,1.5yearsafterreferraltothehospital
and even after participation in a risk factor screening
programme, prevalences were 43% for hypertension, 40% for
hypercholesterolaemia,24%forobesity,and19%forsmoking.
7
Comparable numbers are seen in patients with coronary artery
disease,
8 indicating that a large proportion of patients with a
clinical manifestation of a vascular disease are still at high
residualcardiovascularriskasaresultofnotreachingtreatment
targets as advocated in (inter)national guidelines.
Treatment of vascular risk factors by nurse practitioners has
been shown to be effective in reducing cardiovascular risk
factorsandvascularrisk,
9 10butthistreatmentiscostlyandtime
consumingforpatientsandhealthcareprofessionals,asfrequent
visits to the outpatient clinic are needed. Stimulating self
management has been shown to be effective in lowering blood
pressure,
11 and supporting self management with an internet
programme may add to the effectiveness of the nurse
practitioner’s intervention. Use of the internet is a low cost
method compared with a regular outpatient clinic. Experience
and evidence exist for effective internet based treatment of
depression,
12 13 physical activity in patients with rheumatoid
arthritis,
14painreductioninpatientswithfibromyalgia,
15reduced
mortalityandhospitaladmissioninpatientswithheartfailure,
16
and glucose control in patients with type 2 diabetes.
17-19 In a
small, single centre, uncontrolled, pilot study, an internet based
andnurseledvascularriskreductionprogrammeontopofusual
care was feasible and showed beneficial effects on risk factor
levels after six months.
20 The objective of the multicentre,
randomised trial reported here was to evaluate the effect at one
yearofaninternetbased,nurseledprogrammeformanagement
ofvascularriskfactorsonvascularriskandvascularriskfactors
in patients with clinically manifest vascular disease.
Methods
Trial design
Thestudywasamulticentre,prospective,randomisedcontrolled
trialcomparinginterventionviatheinternetplususualcarewith
usual care alone. The local study coordinator used an online
randomisation procedure with a printed confirmation. The
overallstudycoordinatorcheckedparticipants’assignmentwith
the printed confirmation.
Study population
All randomised patients had a recent clinical manifestation of
atherosclerosis in the coronary, cerebral, or peripheral arteries
diagnosedandwerereferredbytheirvascularspecialist(vascular
surgeon, cardiologist, neurologist) or their general practitioner
at the Rijnstate Hospital Arnhem, the Netherlands, a teaching
hospital,andattheUniversityMedicalCenterUtrecht,Utrecht,
the Netherlands.
Vascular risk factors were measured as part of routine clinical
practice. Patients aged between 18 and 80 years were eligible
for participation in the study if at least two of the following six
treatable risk factors were not at target: systolic blood pressure
above 140 mm Hg, low density lipoprotein cholesterol above
2.5 mmol/L, triglycerides above 1.7 mmol/L, body mass index
above 25, diabetes or fasting glucose above 6.1 mmol/L, and
smoking. Patients had to be able to read and write Dutch, to be
independent in daily activities (Rankin score <3),
21 22 and to
have access to the internet at home. Patients with an estimated
life expectancy less than two years or a malignant disease were
not included in the study.
Internet based, nurse led risk factor
programme and usual care
Patients who met the inclusion criteria and did not met the
exclusion criteria were invited to participate in the study. After
giving written informed consent, patients were randomised to
receive either internet based care or usual care.
Patients randomised to the internet programme received an
internet based programme of vascular risk factor management
ontopofusualcareduringoneyear.Forthispurpose,awebsite
was constructed and tested in a pilot study,
20 and several
improvements were made on the basis of evaluation of the
website by patients in the pilot study. The website was
developed using Microsoft Visual Studio 2005 (development
environment) in Visual C# (programming language). It uses a
Microsoft SQL Server 2005 database for data storage. The
scripts for the website can be obtained from the corresponding
author. At the start, patients were invited for a one hour visit to
the outpatient clinic of the nurse practitioner in the hospital. At
thisvisit,patientsreceivedinformationontheirriskfactorlevels,
instructions about the internet programme, and a username and
password for their personalised website. Subsequent contacts
betweenpatientandnursepractitionerwerethroughtheinternet,
andnofurtheroutpatientclinicvisitswerescheduled.Depending
onthepresenceofriskfactorsthatneeded(additional)treatment,
the nurse practitioner personalised the website for each
individual patient, taking on average 10 minutes. The opening
page showed an overview of the actual status of all risk factors
(green=at goal, yellow=close to goal, red=needs attention) and
drug use (supplementary figure A). Within the personalised
website, each risk factor was displayed on a separate internet
page containing a history of risk factor measurements (such as
bloodpressureorlowdensitylipoproteincholesterol),druguse,
treatmentgoal,advicefromthenurse,correspondencebetween
nurse and patient, and news items for that particular risk factor
(supplementary figure B). Patients were instructed to use the
website as frequently as considered convenient and necessary
at their own discretion and to log in at least every other week
to submit new measurements (blood pressure, weight, smoking
status, cholesterol) and to read and send messages.
The internet programme was linked to the website of the
University Medical Center Utrecht for general information on
risk factors and vascular diseases. The nurse practitioner was
able to view all files and pages from all patients and had access
to pages with a total overview of the current status of risk
factors, last log-in attempts of each patient, and new messages
sent by patients. The treating nurse practitioner logged in every
working day and replied to messages sent by patients and sent
messages to patients not using the programme at least every
other week. In case of non-response by a patient, the nurse
contacted patients by phone. Patients were encouraged to
measure their own blood pressure at home or ask the general
practitioner to measure their blood pressure. Patients were free
to use their own device, as this reflects daily clinical practice.
For measuring plasma lipids and glucose, patients received
laboratory forms from the nurse by mail for blood to be drawn
in their own city or at the University Medical Center Utrecht
or Rijnstate Hospital Arnhem, whichever was convenient for
thepatient.Thenursepractitionerworkedaccordingtothe2006
Dutch cardiovascular risk management guideline,
23 which is
closely related to the 2003 ESC/EAS guidelines,
24 for the
diagnosis and treatment of vascular risk factors. Internists
supervised the nurse practitioners. Changes in drug regimen
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RESEARCHwere made by sending prescriptions to patients by regular mail.
The care delivered by the nurse practitioner with the internet
programme was on top of usual care and did not replace the
care given by the treating physician in the hospital and the
general practitioner.
The usual care given by the medical specialist or general
practitioner was also based on the 2006 Dutch cardiovascular
risk management guideline. The guideline was applicable for
primary care and hospital care. Patients randomised to usual
care were asked to contact their treating physician (vascular
surgeon, cardiologist, neurologist) at the hospital or the general
practitioner for risk factor management. The treating physician
andthegeneralpractitionerwerealsoinformedoftheriskfactor
status in writing. The treating physician was free to determine
the frequency of control. This could range from an annual visit
for a patient with stable coronary artery disease to every three
months for a patient with type 2 diabetes mellitus.
Study measurements
At baseline, drug use, exercise, and smoking were registered;
blood pressure, weight, height, and waist circumference were
measured; fasting blood was drawn for measurement of lipids,
glucose,andcreatinine;andurinewasanalysedforalbuminuria.
After12months,allpatientsinbothgroupswereaskedtoreturn
to the clinic for the same measurements. Independent research
nursesnotawareofthetreatmentallocationofthepatientsmade
the follow-up measurements. We used the four variable
modification of diet in renal disease (MDRD) equation to
calculate estimated glomerular filtration rate.
25 We defined
albuminuriaasaurinealbumin:creatinineratioof2.5mg/mmol
or above in men and 3.5 mg/mmol or above in women.
26 We
defined type 2 diabetes mellitus as a referral with a diagnosis
of type 2 diabetes mellitus, use of glucose lowering drugs, or a
fastingglucoseconcentrationofatleast7.0mmol/Latscreening.
Primary and secondary endpoints
The primary endpoint was the relative change in Framingham
heart risk score after one year.
27 This was calculated as the
difference between the groups in change in Framingham heart
risk score from baseline to one year follow-up: ((baseline
Framinghamheartriskminusfollow-upFraminghamheartrisk
in usual care group) minus (baseline Framingham heart risk
minusfollow-upFraminghamheartriskininterventiongroup))
divided by the mean Framingham heart risk score at baseline.
We calculated the Framingham heart risk score for each
individual patient at baseline and after one year’s follow-up on
thebasisofactualriskfactorlevels.TheFraminghamheartrisk
score represents the predicted 10 year risk for coronary heart
disease and was developed for patients free of vascular disease.
In this study, we used the Framingham heart risk score as a
summaryscoreofvascularriskfactors.
28Theestimatedabsolute
risk level by Framingham heart risk cannot be regarded as a
precise reflection of actual risk,
29 but absolute change in
Framingham heart risk over time is likely to reflect absolute
changes in risk.
The secondary endpoints were the differences between the
intervention and usual care groups in the absolute changes in
the levels of risk factors (level at one year minus level at
baseline) and the differences between groups in the change in
theproportionofpatientsreachingtreatmentgoalsforeachrisk
factor.
Sample size calculation
For the primary outcome, we aimed to detect a 10% relative
difference in the Framingham heart risk score between the two
groups on the basis of a pilot study.
20 We considered this to be
a minimal clinically relevant difference. In the pilot study
(n=50),wefoundachangeinFraminghamheartriskscorefrom
11.2 (SD 7.8) to 9.0 (5.8): difference −2.2 (6.0). For the study
reported here, we recruited patients from among participants in
anongoingcohortstudywithahighermeanagethanthepatients
in the pilot study and a higher Framingham heart risk score of
20%. For the sample size calculation, we used an absolute
change in Framingham heart risk score of −2.0 (6.0), an α of
0.05, and a power of 80%. The calculated sample size was 146
patients in each group.
Adverse events and clinical endpoints
During follow-up, patients were asked to complete a
questionnaire by internet every three months, to report newly
diagnosed diseases and hospital admissions. When a
cardiovascular event was suspected, we retrieved patients’
medicalrecordsanddocumentationfromtheirtreatingspecialist
or general practitioner. Three independent non-treating
specialists separately assessed suspected vascular events and
mortality. Registered events included vascular interventions
(such as percutaneous coronary artery interventions), stroke,
myocardial infarction, vascular mortality, and other severe
adverseevents(alleventscausingdeath,lifethreateningevents,
events requiring at least one night of hospital stay or prolonged
hospital stay, or events causing significant invalidity or labour
incapacity)andnon-severeadverseevents(anyreportedevent).
Data analyses
We expressed results as means with standard deviations or as
absolutenumbersandpercentages.Weexpressednon-normally
distributed variables as median and interquartile range. We
present absolute changes in Framingham heart risk score and
individual risk factors between baseline and follow-up, with
95% confidence intervals, in complete case analyses. We also
calculated the change in percentages of patients who achieved
treatment goals for individual risk factors in both groups. We
usedanindependentsamplettesttoassessdifferencesbetween
groups in absolute changes in Framingham heart risk score and
risk factors between baseline and 12 months’ follow-up and
differences between groups in the proportion of patients
achieving treatment goals. We did sensitivity analyses by
imputing the missing values with the last observation carried
forward, truncation of extreme values, and calculation of the
intervention result by linear regression with adjustment for
baseline risk. We used SPSS statistics 18.0.2 for all statistical
analyses.
Results
Baseline characteristics
PatientswererecruitedbetweenOctober2008andMarch2010.
A total of 638 patients who fulfilled the inclusion criteria were
invited for participation, of whom 330 were randomised (fig
1⇓). The mean age was 59.9 (SD 8.4) years, and most patients
(75%) were male (table 1⇓). All patients had a recent
manifestation of vascular disease diagnosed; most often (49%)
this was coronary artery disease. Mean low density lipoprotein
cholesterol was 2.8 (0.9) mmol/L, and mean systolic blood
pressure was 140 (18) mm Hg.
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RESEARCHThe main reason for not participating in the study was the
absence of internet access or basic computer skills (58%).
Patients not randomised were slightly older (62.1 (10.7) v 59.9
(8.4) years) and more often female (33% v 25%) than
randomised patients (supplementary table A).
Duringthestudy,16(5%)patientsdroppedoutanddidnothave
afollow-upmeasurement.Thosepatientsseemedtobeofsimilar
age to the patients with complete follow-up (59.6 (8.0) v 59.9
(8.4) years), were more often female (37% v 25%), and seemed
tohaveaworseriskfactorprofile(Framinghamheartriskscore
18.1 (19.1) v 15.0 (10.6)) (table 2⇓).
Difference in change in Framingham heart
risk score between intervention and control
groups
After one year, we found a relative change of −14% (95%
confidence interval −25% to −2%) in Framingham heart risk
score in the intervention group compared with the usual care
group.Atbaseline,theFraminghamheartriskscorewashigher
in the intervention group than in the usual care group (16.1
(10.6) v 14.0 (10.5)). Therefore, we used linear regression
analysis to adjust the outcome for the separate variables of the
Framingham heart risk score (age, sex, systolic blood pressure,
low density lipoprotein cholesterol, high density lipoprotein
cholesterol, type 2 diabetes mellitus, and current smoking) and
for the baseline level of the Framingham heart risk score. This
produced a relative change of −12% (−22% to −3%) in
Framinghamheartriskscoreintheinterventiongroupcompared
with the usual care group when adjusted for the separate
variables of the Framingham heart risk score and −8% (−18%
to 2%) when adjusted for the baseline level of the Framingham
heart risk score (table 3⇓). The range of the Framingham heart
risk score was 0.7 to 60.0.
The difference in change in low density lipoprotein cholesterol
was −0.3 (95% confidence interval −0.5 to −0.1) mmol/L
(P<0.001). This translated to a difference between groups in
patients reaching the low density lipoprotein cholesterol goal
of less than 2.5 mmol/L of 18.4% (5.9% to 30.9%; P=0.004).
Intheinterventiongroup,8/42(19%)patientsstoppedsmoking,
compared with four (10%) patients who started smoking in the
usual care group, a difference between groups in change in
patientswhoquitsmokingof7.7%(0.4to14.9;P=0.038)(table
4⇓). Some other risk factors tended to improve (body mass
index, triglycerides, systolic blood pressure, renal function) or
tended to worsen (glucose concentration, albuminuria).
Truncation of extreme values of the Framingham heart risk
score(<1%and>99%centiles)orimputationofmissingvalues
with the last observation carried forward showed similar
differences in change of Framingham heart risk score between
groups (table 5⇓). Stratification for sex, age, type 2 diabetes
mellitus, body mass index, or smoking status produced similar
results (table 5⇓).
Use of the website by patients
Of the 155 patients in the intervention group, 152 patients
actually logged in. They logged in a median of 56 (interquartile
range 35-83) times during the year (supplementary table B).
Patients (n=134) sent a median 14 (7-22) messages, and 131
patients entered a median 7 (3-14) measurements during the
year.Measurementsmostoftenenteredrelatedtobloodpressure
(111patients,median2(2-6))andweight(114patients,median
3 (1-6)). The monthly number of logins decreased during the
intervention period, from a maximum in the third month with
1099 logins to 435 logins in the 12th month (supplementary
figure C). Patients in the highest third of website use had the
highestFraminghamheartriskscore(17.6(10.7)compared14.1
(9.1)inthelowestthird).Patientsinthehighestthirdofwebsite
usehadthelargestchangeinFraminghamheartriskscoreduring
theintervention(−3.8(−6.3to−1.3)comparedwith−1.4(−3.6
to 0.8) in the lowest third) (supplementary table C). During the
one year intervention period, the time spent by nurse
practitioners was on average 23 (12) minutes/month/patient.
Vascular events and other severe adverse
events
Forty patients reported a total of 50 vascular events (table 6⇓).
The intervention was safe, as the hazard ratio for a subsequent
vasculareventwas0.66(95%confidenceinterval0.35to1.24).
The hazard ratio was 0.64 (0.34 to 1.21) after adjustment for
baselineFraminghamheartriskscore.Vasculareventsoccurred
equally throughout the study period, as shown in the
Kaplan-Meier curve (fig 2⇓). Thirty-eight patients reported 47
othersevereadverseevents,ofwhichfivewereseverebleeding
events.
Discussion
This study showed that an internet based, nurse led vascular
preventionprogrammeontopofusualcarecomparedwithusual
care alone resulted in a small relative reduction in the
Framinghamheartriskscoreof14%after12monthsinpatients
with clinically manifest vascular disease. At baseline, the
Framingham heart risk score was higher in the intervention
group than in the usual care group. Therefore, we adjusted the
primary outcome for the separate variables of the Framingham
heart risk score and for the baseline Framingham heart risk
score. The difference in the primary outcome was not
statisticallysignificantafteradjustmentforbaselineFramingham
heart risk score. The clinical importance of this effect is small
and limited. A larger reduction in low density lipoprotein
cholesteroloccurredandalargerproportionofpatientsstopped
smokingintheinterventiongroupcomparedwiththeusualcare
group.
Comparison with other studies
Randomised controlled trials on lowering overall vascular risk
with the use of internet interventions are scarce. In primary
prevention, a two year randomised controlled trial using a
website with education modules and personal tailored
counselling support in 276 healthy overweight participants
showed no significant effect on vascular risk factors, although
several risk factors tended to improve.
30 A cluster randomised
controlledtrialin163patientswithtype2diabeteswhoreceived
the combined intervention of behavioural mobile phone and
internet coaching with presentation of blood glucose
concentrations, lifestyle measurements, and self management
support was effective in reducing glycated haemoglobin levels
afteroneyearby1.2%(95%confidenceinterval0.6%to1.8%)
compared with a control group.
17 In that study, no differences
in blood pressure or plasma lipid concentrations were seen
betweengroups.Inasmallrandomisedcontrolledstudy(n=15)
in patients after a myocardial infarction, a virtual cardiac
rehabilitation programme—consisting of online intake forms;
one-on-one chat sessions with a nurse, dietitian, and exercise
specialist; downloadable exercise heart rate monitoring;
education; and data monitoring of blood pressure, weight, and
glucose—resulted in significant changes in high density
lipoprotein cholesterol, triglycerides, exercise capacity, and
weekly physical activity after 12 weeks.
31 Evaluation of a web
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RESEARCHbased cardiac rehabilitation programme for patients with
vascular disease, consisting of email contact with a case
manager,educationmodulesassignedbythecasemanager,and
entering of data (for example, number of minutes of exercise,
blood pressure measurements), in combination with the option
of participating in an online discussion group, resulted in a
decrease in body mass index of 0.7 compared with a control
group after six months.
32 In that study, blood pressure, lipid
values,andphysicalexerciseimprovedaswell,butthiswasnot
statistically significant.
Our multicentre randomised controlled trial is the largest study
in this field to date. Sensitivity analysis showed a comparable
result in subgroups, and the intervention could probably be
widelyimplemented.Theresultsofthisstudycanbegeneralised
topatientswithaccesstotheinternetathomeandwithsufficient
computerskills.Thenumberofpatientswithoutinternetaccess
or with no computer skills is likely to decrease in the coming
years, including in the older age groups.
33 This could broaden
the applicability of the intervention in the future. Our study had
an age limit of 80 years. More widespread use of the internet
by older people could make this an effective and efficient
interventionforthoselessabletotravelfrequentlytooutpatient
clinics. We think that adapting the website to use this
intervention in other populations would probably be possible,
but it would require careful planning and testing. Different
populations should be approached differently. For example, a
study about designing a cardiovascular disease prevention
website for Latinos showed that they prefer a website that is
culturallyappropriate,withphotosofamultigenerationalfamily
and available in Spanish.
34
Using the internet for the treatment of vascular risk factors,
which is considered to be a chronic condition, is based on the
chronic care model.
35 36 Crucial elements in this model are
support of self management, support of informed consent, and
organising the healthcare process. All these elements can be
combined via the internet, and patients are able to manage their
own health in the place where it should be managed, in the own
environment at a time of their choice. Some patients reported
technical difficulties with the website. This might be due to
inexperience of participating patients. Also, we did not screen
computer skills beforehand. Screening of computer skills or
extra training might enhance use of the website. Every other
week, a summary of a news item was sent by email to all
interventionpatientsandthewholenewsmessagecouldberead
on the website. This was done to stimulate patients to visit the
website and their personal pages on the website. Starting a
(supervised) forum or a chat function could be considered to
attract patients to the website and to further stimulate self
management. Use of the study website on tablet computers or
on smart phones might increase adherence and could make the
intervention accessible to a larger group of patients.
Strengths and limitations of study
We used a summary score for vascular risk. We realise that the
Framingham heart risk score was not developed for estimating
the vascular risk in patients with clinically manifest vascular
disease.
27 As yet, no such a validated score exists for patients
with vascular diseases. The Framingham heart risk score is not
accurateinestimatingtheabsolutevascularriskinthesepatients,
but it can be used to evaluate relative differences and changes
between groups. Secondly, the endpoint in the study was
difference in change in Framingham heart risk score, which is
a surrogate measure. Although this is likely to translate into a
lower vascular event rate and mortality rate, this can be
investigated only in a clinical endpoint study. We extrapolated
the changes in risk factors during the one year intervention
period to change in 10 year cardiovascular risk. A permanent
change in risk factors is assumed, but to maintain changes in
riskfactorstheinterventionshouldalsocoverthe10yearperiod.
Thirdly, an internet based and nurse led intervention might be
cost effective, as the intervention is at least equally effective
and could partly replace more expensive care by medical
doctors. Cost effectiveness will be evaluated in a formal cost
effective analysis. Fourthly, the duration of the intervention
including the follow-up was one year, so the length of smoking
cessation was by definition less than a year. This is a short
periodtoensurethatapatientreallystoppedsmoking.Accuracy
could be enhanced by extending the follow-up period. Fifthly,
animbalanceinriskfactorsbetweengroupsexistedatbaseline,
translating in a difference in the baseline level of the
Framinghamheartriskscore.Theinterventionhadasmalleffect
on lowering the absolute level of the Framingham heart risk
score. This effect was statistically significant after adjustment
for the separate variables of the Framingham heart risk score
and not statistically significant when adjusted for the baseline
Framingham heart risk score. Nevertheless, we think that the
results are important and consistent considering the results of
the secondary endpoints and subgroup analyses.
Conclusions and policy implications
An internet based, nurse led treatment programme on top of
usualcareforvascularriskfactorshadasmalleffectonlowering
vascular risk and on lowering of some vascular risk factors in
patients with vascular disease. The intervention used in this
study is easy to implement in clinical practice at low cost and
could be used for various groups of patients at high
cardiovascular risk.
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RESEARCHWhat is already known on this topic
Treatment of vascular risk factors, alone or in combination, is known to be very effective in reducing the risk of recurrent vascular events
and death
However, in daily clinical practice, treatment goals are often not reached
What this study adds
An internet based, nurse led treatment programme on top of usual care had a small effect on lowering vascular risk and on lowering of
some vascular risk factors in patients with vascular disease
The intervention used is easy to implement in clinical practice at low cost and could be used for various groups of patients at high
cardiovascular risk
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RESEARCHTables
Table 1| Baseline characteristics. Values are numbers (percentages) unless stated otherwise
Usual care group (n=166) Intervention group (n=164)
Demographics and baseline measurements
59.2 (8.9) 60.7 (7.8) Mean (SD) age (years)
118 (71) 128 (78) Male sex
27.4 (3.9) 28.2 (4.1) Mean (SD) body mass index (kg/m²)
4.7 (1.0) 4.7 (1.1) Mean (SD) total cholesterol (mmol/L)
1.2 (0.3) 1.2 (0.3) Mean (SD) HDL cholesterol (mmol/L)
1.7 (1.1) 1.8 (1.1) Mean (SD) triglycerides (mmol/L)
2.8 (0.9) 2.8 (0.9) Mean (SD) LDL cholesterol (mmol/L)
6.3 (1.5) 6.3 (1.4) Mean (SD) glucose (mmol/L)
139 (18) 140 (18) Mean (SD) systolic BP (mm Hg)
80 (10) 81 (10) Mean (SD) diastolic BP (mm Hg)
80 (17) 80 (18) Mean (SD) eGFR (mL/min/1.73 m²)
20 (12) 20 (12) Albuminuria
Vascular disease at inclusion
69 (42) 75 (46) Coronary artery disease
51 (31) 44 (27) Cerebral vascular disease
8 (5) 7 (4) Abdominal aortic aneurysm
38 (23) 38 (23) Peripheral vascular disease
Medical history
77 (46) 86 (52) Coronary artery disease
51 (31) 40 (24) Cerebral vascular disease
5 (3) 3 (2) Abdominal aortic aneurysm
23 (14) 26 (16) Peripheral vascular disease
34 (20) 43 (26) Type 2 diabetes mellitus
44 (27) 43 (26) Current smoking
92 (55) 77 (47) Family history of cardiovascular disease
Drug use
153 (92) 154 (94) Platelet aggregation inhibitor
140 (84) 142 (87) Lipid lowering drug
113 (68) 130 (79) Blood pressure lowering drug
23 (14) 29 (18) Glucose lowering drug
BP=blood pressure; eGFR=estimated glomerular filtration rate; HDL=high density lipoprotein; LDL=low density lipoprotein.
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RESEARCHTable 2| Baseline characteristics of dropouts and analysed patients
Analysed patients (n=314) Dropouts (n=16) Characteristics
59.9 (8.4) 59.6 (8.0) Mean (SD) age (years)
236 (75) 10 (63) No (%) male
27.8 (4.0) 27.5 (4.1) Mean (SD) body mass index (kg/m²)
2.7 (0.9) 3.1 (1.0) Mean (SD) LDL cholesterol (mmol/L)
139 (18) 149 (22) Mean (SD) systolic blood pressure (mm Hg)
83 (26) 4 (25) No (%) current smokers
15.0 (10.6) 18.1 (19.1) Mean (SD) Framingham heart risk score
LDL=low density lipoprotein.
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RESEARCHTable 3| Difference in change in Framingham heart risk score and vascular risk factors between intervention group and usual care group
Relative change†
(95% CI) Difference* (95%CI)
Usual care (n=159) Intervention (n=155)
Risk factor/score Follow-up Baseline Follow-up Baseline
−14% (−25% to −2%) −2.1 (−3.8 to −0.3) 13.2 (9.4) 14.0 (10.5) 13.2 (8.9) 16.1 (10.6) Framingham heart risk score
−12% (−22% to
−3%)‡
−1.8 (−3.3 to −0.4)‡
−8% (−18% to 2%)§ −1.2 (−2.7 to 0.3)§
— 59.1 (8.9) — 60.8 (7.9) Age (years)
— 115 (72) — 121 (78) Male sex
−0.1 (−0.5 to 0.4) 27.9 (4.2) 27.5 (3.9) 28.6 (4.1) 28.2 (4.2) Body mass index (kg/m²)
−0.3 (−0.5 to −0.1) 4.5 (1.0) 4.7 (1.0) 4.3 (0.9) 4.7 (1.0) Total cholesterol (mmol/L)
0.0 (−0.1 to 0.0) 1.3 (0.4) 1.2 (0.3) 1.3 (0.4) 1.2 (0.3) HDL cholesterol (mmol/L)
0.1 (−0.1 to 0.4) 1.4 (0.7) 1.7 (1.2) 1.6 (1.2) 1.8 (1.1) Triglycerides (mmol/L)
−0.3 (−0.5 to −0.1) 2.6 (0.9) 2.7 (0.9) 2.3 (0.7) 2.8 (0.9) LDL cholesterol (mmol/L)
0.1 (−0.1 to 0.4) 6.3 (1.7) 6.3 (1.4) 6.4 (1.5) 6.3 (1.5) Glucose (mmol/L)
0.0 (−0.1 to 0.1) 5.9 (0.7) 5.7 (0.7) 5.9 (0.9) 5.8 (0.7) HbA1c (%)
−3.7 (−7.6 to 0.2) 140 (19) 138 (18) 137 (18) 140 (17) Systolic BP (mm Hg)
−2.0 (−4.4 to 0.4) 80 (10) 79 (10) 80 (9) 81 (10) Diastolic BP (mmHg)
0.9 (−1.6 to 3.4) 79 (17) 80 (17) 80 (18) 80 (18) eGFR (mL/min/1.73 m²)
0.7 (−6.6 to 8.1) 18 (11) 18 (11) 25 (16) 20 (13) Albuminuria
Data are expressed as mean (SD) or number (percentage).
BP=blood pressure; eGFR=estimated glomerular filtration rate; HDL=high density lipoprotein; LDL=low density lipoprotein.
*Difference between groups=(baseline value–follow-up value in usual care group)−(baseline value–follow-up value in intervention group).
†Relative change calculated by dividing by mean Framingham heart risk score at baseline and multiplying by 100.
‡Adjusted for baseline age, sex, systolic blood pressure, LDL cholesterol, HDL cholesterol, type 2 diabetes mellitus, and current smoking.
§Adjusted for baseline Framingham heart risk score.
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RESEARCHTable 4| Difference in change in risk factors at target and drug use between intervention group and usual care groups
Difference* (95% CI)
Usual care (n=159) Intervention (n=155)
Follow-up Baseline Follow-up Baseline
Risk factors
2.0 (−10.5 to 14.5) 54 50 54 48 Systolic blood pressure <140 mm Hg
18.4 (5.9 to 30.9) 48 41 65 39 LDL cholesterol <2.5 mmol/L
2.0 (−7.7 to 11.8) 72 69 66 60 HDL cholesterol: women ≥1.30, men ≥1.0 mmol/L
5.9 (−5.4 to 17.2) 71 64 68 55 Triglycerides <1.7 mmol/L
−6.4 (−16.7 to 3.9) 58 55 52 55 Fasting glucose <6.1 mmol/L
3.9 (−1.8 to 9.6) 23 26 17 16 Body mass index <25.0 kg/m²
2.5 (−7.0 to 12.0) 44 53 42 45 Waist: women <88, men <102 cm
7.7 (0.4 to 14.9) 72 74 78 73 No smoking
0.0 (−5.0 to 5.1) 22 20 28 26 Type 2 diabetes mellitus:
1.0 (−22.2 to 24.1) 74 78 67 69 HbA1c <7%, <53 mmol/mol
−18.9 (−46.4 to 8.6) 57 41 60 60 Fasting glucose <8 mmol/L
−2.5 (−18.9 to 13.8) 74 69 72 65 Glucose lowering drugs
0.4 (0.1 to 0.6) 3.3 (1.2) 3.1 (1.2) 3.4 (1.2) 2.9 (1.2) Mean (SD) No of risk factors on target†
Drug use
2.6 (−2.1 to 7.3) 97 97 99 97 Vascular disease treatment‡:
2.7 (−3.7 to 9.1) 94 93 98 94 Platelet aggregation inhibitor
0.8 (−7.7 to 9.2) 88 86 90 86 Lipid lowering drug
−5.0 (−11.7 to 1.6) 75 69 80 79 Blood pressure lowering drugs
Data are expressed as percentage or mean (SD).
HDL=high density lipoprotein; LDL=low density lipoprotein.
*Difference=(baseline value–follow-up value in usual care group)−(baseline value–follow-up value in intervention group).
†Risk factors: systolic blood pressure, LDL cholesterol, triglycerides, glucose, body mass index, smoking.
‡Platelet aggregation inhibitors, lipid lowering drugs, blood pressure lowering drugs.
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RESEARCHTable 5| Sensitivity analyses
Difference in FHR between intervention and usual care (95%CI) Adjustments/subgroups
−2.1 (−3.8 to −0.3) No adjustments
−1.8 (−3.3 to −0.4) Adjusted for baseline age, sex, SBP, LDL-c, HDL-c, type 2 diabetes, current smoking
−1.2 (−2.7 to 0.3) Adjusted for baseline FHR score
−1.8 (−3.5 to −0.2) FHR score truncated at 1% and 99%
−2.1 (−3.8 to −0.4) Last observation carried forward
−2.1 (−4.3 to 0.2) Men
−1.8 (−3.9 to 0.3) Women
−1.7 (−3.5 to 0.1) Age under 61 years*
−2.5 (−5.8 to 0.8) Age over 61 years
−1.9 (−3.6 to −0.2) No type 2 diabetes mellitus
−2.1 (−7.2 to 3.1) Type 2 diabetes mellitus
−1.5 (−3.7 to 0.8) Body mass index under 27 kg/m²*
−2.6 (−5.2 to 0.0) Body mass index over 27 kg/m²
−2.7 (−4.3 to −1.0) No smoking
−0.2 (−4.7 to 4.3) Smoking
FHR=Framingham heart risk; HDL-c=high density lipoprotein cholesterol; LDL-c=low density lipoprotein cholesterol; SBP=systolic blood pressure.
*Stratified at median value.
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RESEARCHTable 6| Adverse events
Usual care group Intervention group
Events No of patients No of events No of patients No of events
24 32 16 18 All vascular events*:
6 6 0 0 Myocardial infarction
1 1 0 0 Fatal cerebrovascular event
20 25 16 18 Vascular intervention
16 21 22 26 Other severe adverse events†:
4 4 1 1 Severe bleeding
40 53 38 44 Total severe adverse events
4 14 15 17 Other adverse events‡
*Vascular interventions, stroke, myocardial infarction, vascular mortality.
†Death, life threatening events, events requiring at least one night of hospital stay or prolonging of hospital stay, events causing significant invalidity or labour
incapacity.
‡Any reported event.
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RESEARCHFigures
Fig 1 Flow chart of study
Fig 2 Kaplan-Meier curve for vascular events
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